<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Food and Drug Administration Center for Drug Evaluation and Research United States Department of Health and Human Services Rintatolimod Chronic Fatigue Syndrome Advisory Committee Drug development Off-label use Pharmacology Pharmaceutical sciences Clinical research |
Add to Reading List |
Microsoft Word[removed]Stakeholder Teleconference Transcript.doc | CENTER FOR DRUG EVALUATION AND RESEARCH DRUG SAFETY PRIORITIES 2017DocID: 1ueGS - View Document |
 | CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208573Orig1s000 SUMMARY REVIEWDocID: 1t19G - View Document |
 | CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022526Orig1s000 SUMMARY REVIEWDocID: 1sZi5 - View Document |
 | MEMORANDUM DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCHDocID: 1sPXO - View Document |
 | Abstract # 2639 Enhanced (Q)SAR Models for Prediction Rodent Carcinogenicity Naomi L. Kruhlak1, Dongyu Guo1, Kevin P. Cross2, Lidiya Stavitskaya1 FDA Center for Drug Evaluation and Research (CDER), 10903 New Hampshire ADocID: 1swgc - View Document |